Previous 10 | Next 10 |
home / stock / aconw / aconw news
Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel of 10 Key Opinion Leader (KOL) surgeons All commercial Nociscans to date have been completed...
Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care. Aclarion’s KOL panel represents spine surgeons at some of the largest and most influe...
Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian Och Spine. Dr. Hartl becomes Aclarion’s 2 nd KOL to get access to an MRI center a...
The Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, is funding ground-breaking low back pain research. The Back Pain Consortium (BACPAC) Research Program, a recipient of the NIH HEAL Initiative, is an effort to address the need for effective and personalized...
Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain George Frey, MD Becomes Aclarion’s First KOL Surgeon to Onboard a Hospital MRI to add Nociscan Dat...
Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45 th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023. Founded in 1979, SMDM promotes scientific and methodological rigor in health care decis...
Partnership aims to include Aclarion’s Nociscan surgical decisioning technology within ATEC’s AlphaInformatiX platform to better inform spine surgery ATEC is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction Acla...
Aclarion is steadily executing on a proven path toward standard of care. Ten prominent Key Opinion Leader (KOL) surgeons have formally engaged to partner with the company to drive market traction and reimbursement. Company is poised to report the critical metrics that drive the key cataly...
BROOMFIELD, CO, Aug. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help ph...
BROOMFIELD, CO, June 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algori...
News, Short Squeeze, Breakout and More Instantly...
Aclarion Inc. Warrant Company Name:
ACONW Stock Symbol:
NASDAQ Market:
LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation Norway is a single-payer national health insurance system LIFEHAB is targeting enrollment to begin in the second quarter of 2024 BROOMFIELD, CO,...
Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons. BROOMFIELD, CO, March 04, 2024 (GLOBE NEWS...
BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help...